Research
Print page Print page
Switch language
Hvidovre Hospital - a part of Copenhagen University Hospital
Published

Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

Research output: Contribution to journalJournal articlepeer-review

  1. HIV infection is associated with type 2 diabetes mellitus

    Research output: Contribution to journalLetterpeer-review

  1. Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail

    Research output: Contribution to journalJournal articlepeer-review

  2. Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review

    Research output: Contribution to journalReviewpeer-review

View graph of relations

BACKGROUND: Despite increased integrase strand transfer inhibitor (INSTI) use, limited large-scale, real-life data exists on INSTI uptake and discontinuation.

SETTING: International multicohort collaboration.

METHODS: RESPOND participants starting dolutegravir (DTG), elvitegravir (EVG), or raltegravir (RAL) after January 1, 2012 were included. Predictors of INSTI used were assessed using multinomial logistic regression. Kaplan-Meier and Cox proportional hazards models describe time to and factors associated with discontinuation.

RESULTS: Overall, 9702 persons were included; 5051 (52.1%) starting DTG, 1933 (19.9%) EVG, and 2718 (28.0%) RAL. The likelihood of starting RAL or EVG vs DTG decreased over time and was higher in Eastern and Southern Europe compared with Western Europe. At 6 months after initiation, 8.9% (95% confidence interval: 8.3% to 9.5%) had discontinued the INSTI (6.4% DTG, 7.4% EVG, and 14.0% RAL). The main reason for discontinuation was toxicity (44.2% DTG, 42.5% EVG, 17.3% RAL). Nervous system toxicity accounted for a higher proportion of toxicity discontinuations on DTG (31.8% DTG, 23.4% EVG, 6.6% RAL). Overall, treatment simplification was highest on RAL (2.7% DTG, 1.6% EVG, and 19.8% RAL). Factors associated with a higher discontinuation risk included increasing year of INSTI initiation, female gender, hepatitis C coinfection, and previous non-AIDS-defining malignancies. Individuals in Southern and Eastern Europe were less likely to discontinue. Similar results were seen for discontinuations after 6 months.

CONCLUSIONS: Uptake of DTG vs EVG or RAL increased over time. Discontinuation within 6 months was mainly due to toxicity; nervous system toxicity was highest on DTG. Discontinuation was highest on RAL, mainly because of treatment simplification.

Original languageEnglish
JournalJournal of acquired immune deficiency syndromes (1999)
Volume83
Issue number3
Pages (from-to)240-250
Number of pages11
ISSN1525-4135
DOIs
Publication statusPublished - 1 Mar 2020

ID: 59340124